Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Ave Complutense 40, 28040 Madrid, Spain.
Biomedical Research Institute I+12, University Hospital "12 de Octubre", 28041 Madrid, Spain.
Int J Mol Sci. 2021 Mar 10;22(6):2818. doi: 10.3390/ijms22062818.
Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology. The high incidence, prevalence, and progression of BC have led to the exploration of new avenues in its management, in particular in advanced metastatic stages. The recent inclusion of immune checkpoint blockade inhibitors as a therapeutic option for BC represents an unprecedented advance in BC management. However, although some patients show durable responses, the fraction of patients showing benefit is still limited. Notwithstanding, cell-based therapies, initially developed for the management of hematological cancers by infusing immune or trained immune cells or after the engineering of chimeric antigen receptor (CAR) expressing cells, are promising tools to control, or even cure, solid tumors. In this review, we summarize recent cell-based immunotherapy studies, with a special focus on BC.
目前，膀胱癌（BC）是肿瘤学领域面临的一个极具挑战性的问题。BC 的高发病率、患病率和进展导致人们探索其管理的新途径，特别是在晚期转移性阶段。最近，免疫检查点抑制剂被纳入 BC 的治疗选择，这是 BC 管理的一个前所未有的进展。然而，尽管一些患者表现出持久的反应，但受益的患者比例仍然有限。尽管如此，细胞疗法最初是为了通过输注免疫或训练有素的免疫细胞或在表达嵌合抗原受体（CAR）的细胞工程后，用于治疗血液系统癌症而开发的，是控制甚至治愈实体瘤的有前途的工具。在这篇综述中，我们总结了最近的细胞免疫治疗研究，特别关注 BC。
